Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Outer inflammatory protein A (OipA) is a significant outer membrane protein and virulence factor of the gastric pathogen Helicobacter pylori (Yamaoka et al., 2000, PubMed: 10948120). It functions primarily as an adhesin, playing a critical role in the attachment of the bacterium to the gastric mucosa, which is essential for persistent infection and colonization (Dossumbekova et al., 2006, PubMed: 16912302). In addition to its adhesive properties, OipA acts as a potent pro-inflammatory stimulus, triggering the production of interleukin-8 (IL-8) in gastric epithelial cells via the activation of the NF-κB and MAPK signaling cascades (Yamaoka et al., 2004, PubMed: 15258109). The expression of OipA is regulated by a phase-variation mechanism involving slipped-strand mispairing in the 5' region of the hopH gene, resulting in functional "on" or "off" states (Teymournejad et al., 2017, PubMed: 28414018). Strains with the OipA "on" status are strongly associated with higher bacterial loads, increased gastric inflammation, and a significantly elevated risk of developing duodenal ulcers and gastric adenocarcinoma (Kudo et al., 2004, PubMed: 15557550). Due to its surface exposure and central role in H. pylori pathogenesis, OipA is a prominent target for the development of vaccines and novel antimicrobial agents designed to block bacterial adhesion (Liu et al., 2020, PubMed: 32153485).
OipA facilitates Helicobacter pylori adhesion to gastric epithelial cells and triggers pro-inflammatory signaling cascades, including the NF-κB and MAPK pathways, leading to the production of interleukin-8 (IL-8) (Yamaoka et al., 2004, PubMed: 15258109; Dossumbekova et al., 2006, PubMed: 16912302).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Outer inflammatory protein A (OipA) (OipA).